The PI3K – mTOR Pathway
How and why we target the PI3K and mTOR pathway in cancer
Pursuing first-in-class targeted therapies
The PI3K/mTOR pathway has been implicated in breast, prostate, endometrial, ovarian and hematological cancers, among others.
We are currently developing our lead drug candidate, gedatolisib, in metastatic breast cancer.
Therapeutic Pipeline: Gedatolisib
The safety and efficacy of investigational agents and/or investigational use of approved products have not been established. Ibrance® is a registered trademark of Pfizer, Inc.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; MT, mutated; BRCA, Breast Cancer Gene; TNBC, Triple Negative Breast Cancer; HNSCC, head and neck squamous cell carcinoma; SCLC, squamous cell lung cancer; mCRPC, metastatic castration resistant prostate cancer.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha; MT, mutated; BRCA, Breast Cancer Gene; TNBC, Triple Negative Breast Cancer; HNSCC, head and neck squamous cell carcinoma; SCLC, squamous cell lung cancer; mCRPC, metastatic castration resistant prostate cancer.
Gedatolisib
Internal development of a pan-PI3K/mTOR inhibitor
Companion Diagnostic Pipeline: CELsignia
We are using our CELsignia platform to expand new indications for already approved targeted therapies.
